Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies
Abstract
Thoracic malignancies are associated with high mortality rates. Conventional therapy for many of the patients with thoracic malignancies is obviated by a high incidence of locoregional recurrence and distant metastasis. Fortunately, developments in immunotherapy provide effective strategies for both local and systemic treatments that have rapidly advanced during the last decade. One promising approach to cancer immunotherapy is to use oncolytic viruses, which have the advantages of relatively high tumor specificity, selective replication-mediated oncolysis, enhanced antigen presentation, and potential for delivery of immunogenic payloads such as cytokines, with subsequent elicitation of effective antitumor immunity. Several oncolytic viruses including adenovirus, coxsackievirus B3, herpes virus, measles virus, reovirus, and vaccinia virus have been developed and applied to thoracic cancers in preclinical murine studies and clinical trials. This review discusses the current state of oncolytic virotherapy in lung cancer, esophageal cancer, and metastatic malignant pleural effusions and considers its potential as an emergent therapeutic for these patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 11, 2021
- Source ID
- 10.1245/s10434-020-09477-4
Entities
People
- Adam C Soloff
- Chigozirim N. Ekeke
- David L. Bartlett
- James D. Luketich
- Kira L. Russell
- Kyla Joubert
- Michael T. Lotze
- Rajeev Dhupar
- Zong Sheng Guo
Organizations
- Center for Scientific Review
- Division of Cancer Prevention, National Cancer Institute
- Office of Research, Health Sciences, University of Pittsburgh
- United States Department of Defense